Dawes Karen Ainsider trades
In SEC Form 4 filings, Dawes Karen A is listed as Director of Barinthus Biotherapeutics plc. (BRNS). Dawes Karen A reported no open-market purchases or sales in the last 90 days. The latest Form 4 transaction on record was filed on Sep 9.
Companies and roles
| Company | Role | Transactions | Last filed |
|---|---|---|---|
| BRNSBarinthus Biotherapeutics plc. | Director | 6 | Sep 9 |
Cluster buys
No cluster buy in the last 90 days included a purchase by this insider (two or more insiders buying within 14 days).
Form 4 historysince 2026-09-09
| Company | Traded | Filed | Type | Shares | Price | Value | Owned after | 10b5-1 plan | Filing |
|---|---|---|---|---|---|---|---|---|---|
| BRNSBarinthus Biotherapeutics plc. | Sep 9 | Sep 9 | D | 1,700 | not reported | not reported | not reported | No | Form 4 |
| BRNSBarinthus Biotherapeutics plc. | Sep 9 | Sep 9 | D · derivative | 34,328 | $17.00 | $583,576 | not reported | No | Form 4 |
| BRNSBarinthus Biotherapeutics plc. | Sep 9 | Sep 9 | D · derivative | 18,604 | $4.27 | $79,439 | not reported | No | Form 4 |
| BRNSBarinthus Biotherapeutics plc. | Sep 9 | Sep 9 | D · derivative | 19,197 | $2.27 | $43,577 | not reported | No | Form 4 |
| BRNSBarinthus Biotherapeutics plc. | Sep 9 | Sep 9 | D · derivative | 19,516 | $2.34 | $45,667 | not reported | No | Form 4 |
| BRNSBarinthus Biotherapeutics plc. | Sep 9 | Sep 9 | D · derivative | 20,174 | $1.00 | $20,174 | not reported | No | Form 4 |
Published from this insider's public Form 4 filings on SEC EDGAR; the name is shown as filed. Named in a filing and want this page removed? See the privacy policy.